(MENAFN- Nxtgen Reports) Chronic kidney disease (CKD) means your kidneys are damaged and can't filter blood the way they should. The main risk factors for developing kidney disease are diabetes, high blood pressure, heart disease, and a family history of kidney failure.
The Chronic Kidney Disease (CKD) Drugs market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.
Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.
In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Chronic Kidney Disease (CKD) Drugs industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.
The Chronic Kidney Disease (CKD) Drugs market can be split based on product types, major applications, and important countries as follows:
Key players in the global Chronic Kidney Disease (CKD) Drugs market covered in Chapter 12:
AstraZeneca plc
GlaxoSmithKline plc.
FibroGen Inc
Johnson & Johnson
Amgen Inc.
Teva Pharmaceutical Industries Ltd.
Hoffmann-La Roche Ltd.
Pfizer, Inc.
Allergan plc.
Sanofi S.A.
Keryx Biopharmaceuticals, Inc.
AbbVie, Inc.
Kissei Pharmaceutical Co., Ltd
In Chapter 4 and 14.1, on the basis of types, the Chronic Kidney Disease (CKD) Drugs market from 2015 to 2025 is primarily split into:
Calcium Channel Blockers
Antihypertensive
Anemia Treatment Drugs
Antihyperlipidemic
Erythropoiesis-stimulating Agents (ESAs)
Swelling Treatment Drugs
Beta Blockers
Diuretics
Angiotensin-II Receptor Blockers
ACE Inhibitors
Other Drug Classes
In Chapter 5 and 14.2, on the basis of applications, the Chronic Kidney Disease (CKD) Drugs market from 2015 to 2025 covers:
Specialty Clinics
Hospitals
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
United States
Canada
Mexico
Europe (Covered in Chapter 8 and 14)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 9 and 14)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 10 and 14)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 11 and 14)
Brazil
Argentina
Columbia
Chile
Others
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025
MENAFN14052022004360009250ID1104211532
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.